Table 1 Characteristics of 1464 patients with prostate cancer
Variables | n (%), or median (range, mean ± SD) |
|---|---|
PSA <4 | |
Number of patients | 738 (50.4 %) |
Age (y) | 76 (35–99, 75.3 ± 9.0) |
WBC (/mL) | 5800 (2000–16,100, 6321.3 ± 2203.3) |
Neutrophil (%) | 58.8 (4.5–89.0, 59.5 ± 10.3) |
Lymphocyte (%) | 29.0 (1.0–60.5, 28.6 ± 8.9) |
NLR | 2.02 (0.09–44.5, 2.57 ± 2.33) |
4 ≤ PSA <20 | |
Number of patients | 519 (35.5 %) |
Age (y) | 73 (44–99, 72.8 ± 8.2) |
WBC (/mL) | 5900 (1100–22,800, 6286.1 ± 2056.8) |
Neutrophil (%) | 60.5 (3.0–90.0, 60.6 ± 10.4) |
Lymphocyte (%) | 28.6 (3.0–91.0, 28.6 ± 9.2) |
NLR | 2.11 (0.03–28.67, 2.57 ± 1.99) |
20 ≤ PSA < 100 | |
Number of patients | 113 (7.7 %) |
Age (y) | 76 (54–104, 76.2 ± 8.9) |
WBC (/mL) | 6000 (1400–28,500, 6379.7 ± 3919.7) |
Neutrophil (%) | 61.4 (7.0–96.7, 61.6 ± 13.1) |
Lymphocyte (%) | 27.7 (2.6–82.5, 26.9 ± 11.9) |
NLR | 2.21 (0.08–37.19, 3.64 ± 4.78) |
100 ≤ PSA < 500 | |
Number of patients | 53 (3.6 %) |
Age (y) | 77 (59–99, 78.0 ± 8.6) |
WBC (/mL) | 6300 (1000–26,400, 6664.2 ± 3501.1) |
Neutrophil (%) | 66.0 (25.5–95, 64.1 ± 15.1) |
Lymphocyte (%) | 22.5 (2.5–61.0, 23.3 ± 11.9) |
NLR | 2.83 (0.42–38.00, 4.60 ± 5.75) |
500 ≤ PSA | |
Number of patients | 41 (2.8 %) |
Age (y) | 79 (60–95, 77.3 ± 9.1) |
WBC (/mL) | 6400 (2300–48,800, 7973.2 ± 6909.6) |
Neutrophil (%) | 69.0 (29.0–60.0, 67.0 ± 14.8) |
Lymphocyte (%) | 20.0 (1.5–58.0, 22.2 ± 13.0) |
NLR | 3.33 (0.50–60.00, 6.43 ± 10.49) |